Dr. Nicholas Ostrout earned his PhD in Immunology from Case Western University School of Medicine. Having focused on the development and persistence of memory T cells, Nick immediately saw the potential for the use of this research in cell and gene therapies. After graduating, Nick was hired at a startup company, TreeStar, Inc, that built software used for analyzing large data sets, and developing automated analytical packages, particularly useful for immunological applications in analyzing numerous properties of millions of cells. After holding many positions within TreeStar, from applications development, to sales, to marketing, and program management, Dr. Ostrout decided to move to a more focused cell and gene therapy company at Miltenyi Biotec.

At Miltenyi, Lonza, and Charles River, Dr. Ostrout gained experience across the spectrum of the commercial organization, leading sales teams, licensing therapies, developing commercial partnerships, analyzing new technologies and their application to the CGT field, and building out commercial organizations. Nick served as the primary commercial lead at Lonza in Personalized Medicine, where he led search and evaluation, as well as transactions, for Lonza's business unit, in addition to building out, and leading, the commercial organization, including sales, marketing, and support teams. At Charles River, Nick managed the integration of the newly acquired cell and gene portfolio companies into the broader Charles River organization, supporting all commercial aspects from marketing to sales, and developing the workflow strategy for Cell and Gene assets across CRL. Nick also managed the portfolio partnerships for other advanced modalities (including RNA and mAbs), and developing the strategy for future partnership opportunities. After seeing ViroCell’s utility in the space as a lean CDMO focused on innovative technologies and streamlined manufacturing, Nick decided it was time to make another move and focus on solving the next problem; how to get these valuable, life changing therapies, into the patients that need them most.